| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.091 | 0.02 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.078 | 0.02 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.074 | 0.03 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.096 | 0.03 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.084 | 0.03 |